INDIANAPOLIS, Oct. 29 /PRNewswire/ — Roche (SIX: RO, ROG;
OTCQX: RHHBY) announced today the U.S. introduction of the cobas e
602 analyzer, the latest addition to the cobas® 8000 modular
analyzer series for diagnostic labs with high-volume workloads.
Labs will now be able to combine this new immunoassay module with
two existing clinical chemistry modules to create an integrated
platform with 24 unique system configurations to match their
specific testing needs.
“The cobas e 602 module completes our consolidated
platform solution for high-volume labs by enabling them to
seamlessly integrate clinical chemistry and immunoassay testing on
one system,” said Randy Pritchard, vice president, marketing of
Roche Diagnostics Corporation. “The modular design gives them the
freedom to design a system that meets their needs now and easily
add individual modules as their testing needs change in the
future.”
The cobas e 602 module uses Roche’s patented
electrochemiluminescence (ECL) technology and includes more than 50
assays on its initial test menu. It offers a throughput of up to
170 immunoassay tests per hour and when combined with the existing
clinical chemistry modules (cobas c 701 module / cobas
c 502 module), 10 unique configurations are available, which
offer a throughput of 3,670 to 7,970 tests per hour. The
cobas e 602 module is also available in 4 immunoassay only
configurations, which offer a throughput of 170 to 680 tests per
hour.
About the cobas 8000 modular analyzer seriesThe cobas 8000
series is the newest member of the Roche cobas modular platform
family, combining both clinical chemistry and immunochemistry
testing, and completes the Roche cobas portfolio for laboratories
with low, medium and high testing volumes. The cobas 8000 series is
designed to meet the needs of high-volume laboratories to deliver
high quality results fast and efficiently from a single patient
sample. It features i
‘/>”/>
